Breakthrough in Alzheimer's treatment. Experts are alarming: the Polish system is not keeping up with medicine.

* New drugs lecanemab and donanemab were approved by the European Commission in 2025 for symptomatic patients with early Alzheimer's disease.
* Lecanemab and donanemab work by removing beta-amyloid deposits, with lecanemab also inhibiting further deposition.
* Lecanemab slowed worsening condition by 31-33 percent compared to placebo over 18 months in clinical studies.
* Donanemab slowed the worsening condition by 25 percent in the entire studied population and 37 percent in people with low or moderate tau protein burden.
* In Poland, access to these EU-approved therapies requires appeals from neurologists and patient organizations due to reimbursement limitations.
* About 70 percent of people suspected of dementia do not receive further diagnosis after a visit to primary healthcare.
* Blood tests measuring the p-tau217 protein can help detect biological changes characteristic of Alzheimer's.
* The cost for PET scans detecting amyloid deposits in the brain exceeds 12 thousand zlotys and are generally not reimbursed in Poland.
* In 2050, almost one-third of Poland’s inhabitants will be at least 65 years old.
* Costs for services related to Alzheimer's diagnosis and treatment increased by 104 percent between 2019 and 2025 for patients aged 55 and over with the main diagnosis.

The narrative frames a profound tension between rapid scientific discovery and systemic inertia within the healthcare structure. The emergence of disease-modifying therapies suggests a technological capability to alleviate suffering, yet this potential is immediately constrained by bureaucratic and financial limitations concerning access, diagnosis, and coordination. The discrepancy between cutting-edge biological understanding (biomarkers like p-tau217) and actual patient reality (late diagnosis rates and inaccessible research funding) highlights a failure in translational medicine.
The push for a new care organization and streamlined diagnostic pathways suggests that the problem is less about the science of treatment itself and more about the logistics of implementation—the gap between theoretical medical progress and tangible patient benefit. The focus on creating a short path from symptom to therapy qualification reveals an underlying pattern where systemic fragmentation dictates individual outcomes. Furthermore, recognizing the exponential increase in prevalence among aging populations requires moving beyond episodic treatment to proactive, preventative organization. The challenge is shifting the paradigm from treating symptoms within an inadequate structure to building an infrastructure capable of supporting early recognition and sustained care for complex neurological conditions.
BRIDGE QUESTIONS: If efficient system creation is proposed, what specific accountability mechanisms must be established to ensure that funding priorities shift effectively? How can the reluctance to reimburse high-cost diagnostic modalities be reconciled with the goal of earlier, more accurate diagnosis? What role should patient advocacy play in defining these new organizational structures beyond simply appealing for access?